MPP extends license for Atazanavir treatment for HIV to Ukraine

MPP extends license for Atazanavir treatment for HIV to UkraineThe Medicines Patent Pool (MPP) has extended the license for Atazanavir (ATV), part of the World Health Organization-preferred second-line treatment for adults and children, to Ukraine, the All-Ukrainian Network of People Living with HIV/AIDS (PLWH) has reported on its website.

"Six factories can supply the generic version of Atazanavir in the framework of this license. Thus, it is possible to predict a high competition for this drug that will lead to a sufficiently competitive price for Ukraine," the press service said, citing Policy and Advocacy Director of the All-Ukrainian Network of PLWH Serhiy Dmitriyev.

The agreement for the distribution and production of Atazanavir was reached with the pharmaceutical company Bristol-Myers Squibb.

Compared with the main alternative drug (lopinavir), ATV has certain advantages, such as a smaller number of side effects, being taken once a day, and easier manufacturing, which leads to lower prices.

In total, the license is valid in 122 middle- and low-income countries.
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Март 2019    »